Cargando…

Peptide therapeutics in the management of metastatic cancers

Cancer remains a leading health concern threatening lives of millions of patients worldwide. Peptide-based drugs provide a valuable alternative to chemotherapeutics as they are highly specific, cheap, less toxic and easier to synthesize compared to other drugs. In this review, we have discussed vari...

Descripción completa

Detalles Bibliográficos
Autores principales: Bose, Debopriya, Roy, Laboni, Chatterjee, Subhrangsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345020/
https://www.ncbi.nlm.nih.gov/pubmed/35975072
http://dx.doi.org/10.1039/d2ra02062a
_version_ 1784761338434682880
author Bose, Debopriya
Roy, Laboni
Chatterjee, Subhrangsu
author_facet Bose, Debopriya
Roy, Laboni
Chatterjee, Subhrangsu
author_sort Bose, Debopriya
collection PubMed
description Cancer remains a leading health concern threatening lives of millions of patients worldwide. Peptide-based drugs provide a valuable alternative to chemotherapeutics as they are highly specific, cheap, less toxic and easier to synthesize compared to other drugs. In this review, we have discussed various modes in which peptides are being used to curb cancer. Our review highlights specially the various anti-metastatic peptide-based agents developed by targeting a plethora of cellular factors. Herein we have given a special focus on integrins as targets for peptide drugs, as these molecules play key roles in metastatic progression. The review also discusses use of peptides as anti-cancer vaccines and their efficiency as drug-delivery tools. We hope this work will give the reader a clear idea of the mechanisms of peptide-based anti-cancer therapeutics and encourage the development of superior drugs in the future.
format Online
Article
Text
id pubmed-9345020
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-93450202022-08-15 Peptide therapeutics in the management of metastatic cancers Bose, Debopriya Roy, Laboni Chatterjee, Subhrangsu RSC Adv Chemistry Cancer remains a leading health concern threatening lives of millions of patients worldwide. Peptide-based drugs provide a valuable alternative to chemotherapeutics as they are highly specific, cheap, less toxic and easier to synthesize compared to other drugs. In this review, we have discussed various modes in which peptides are being used to curb cancer. Our review highlights specially the various anti-metastatic peptide-based agents developed by targeting a plethora of cellular factors. Herein we have given a special focus on integrins as targets for peptide drugs, as these molecules play key roles in metastatic progression. The review also discusses use of peptides as anti-cancer vaccines and their efficiency as drug-delivery tools. We hope this work will give the reader a clear idea of the mechanisms of peptide-based anti-cancer therapeutics and encourage the development of superior drugs in the future. The Royal Society of Chemistry 2022-08-02 /pmc/articles/PMC9345020/ /pubmed/35975072 http://dx.doi.org/10.1039/d2ra02062a Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Bose, Debopriya
Roy, Laboni
Chatterjee, Subhrangsu
Peptide therapeutics in the management of metastatic cancers
title Peptide therapeutics in the management of metastatic cancers
title_full Peptide therapeutics in the management of metastatic cancers
title_fullStr Peptide therapeutics in the management of metastatic cancers
title_full_unstemmed Peptide therapeutics in the management of metastatic cancers
title_short Peptide therapeutics in the management of metastatic cancers
title_sort peptide therapeutics in the management of metastatic cancers
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345020/
https://www.ncbi.nlm.nih.gov/pubmed/35975072
http://dx.doi.org/10.1039/d2ra02062a
work_keys_str_mv AT bosedebopriya peptidetherapeuticsinthemanagementofmetastaticcancers
AT roylaboni peptidetherapeuticsinthemanagementofmetastaticcancers
AT chatterjeesubhrangsu peptidetherapeuticsinthemanagementofmetastaticcancers